The study and its comparison
A Dutch multicenter trial randomized 464 pregnant participants with PCOS at 8–16 weeks of gestation. Both groups received folic acid; the intervention added myo-inositol 2 grams twice daily until delivery. [1]
The primary composite occurred in 25.0 percent of the inositol group and 26.8 percent of controls. The relative risk was 0.93, with a confidence interval spanning benefit and harm. [1]
What the finding establishes
The masked comparison does not support claiming prevention of these complications in this population. It did not test conception rates or every inositol ratio. Baseline biochemical hyperandrogenism differed between groups. Authors disclosed several pharmaceutical relationships; trial funding was not established from the retrieved record. [1]
A hypothetical distinction
Imagine a supplement has been discussed for fertility. A pregnancy-complication trial answers a different question.
| Detail | Interpretation |
|---|---|
| Measured outcome | Keep the endpoint specific |
| Study preparation | Not every retail product |
| Remaining uncertainty | Not resolved by a mechanism |
Sources for this article
- Myo-inositol Supplementation to Prevent Pregnancy Complications in Polycystic Ovary Syndrome: A Randomized Clinical Trial.
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.